Rakesh Dixit

Company: Regio Biosciences | Bionavigen

Job title: President, Chief Scientific Officer

Seminars:

Panel Discussion: Overtaking CAR-T & ADCs in Relapsed/Refractory Multiple Myeloma Treatments: How Do Bispecific Therapies Fare in the Clinic? 10:00 am

Setting the scene: bispecific antibodies as next class of treatments for multiple myeloma to emerge in the clinic Comparing the safety and efficacy profiles of these two treatments for a heavily pre-treated patient population Debating combination of the two therapies: which should be used first and does the usage of one prevent the future utility…Read more

day: Conference Day Two

Panel Discussion: Navigating the Unknown: Strategies for Assessing Bispecific Targets Without a Clear Mechanism of Action 12:00 pm

The development of bispecifics targeting novel or poorly understood targets can be challenging when there is no clear understanding of the underlying mechanism of action. This panel discussion will enable you to hear from experts on: The role of preclinical models in identifying potential targets and assessing their suitability for bispecific antibody development The importance…Read more

day: Conference Day One - Target Discovery AM